Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD [clinicaltrials:NCT00064402]

Bio2RDF identifier

NCT00064402

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00064402

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00064402

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

741

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT00064402 arm group a87ff679a2f3e71d9181a67b7542122c [clinicaltrials_resource:NCT00064402/arm-group/a87ff679a2f3e71d9181a67b7542122c]

NCT00064402 arm group c4ca4238a0b923820dcc509a6f75849b [clinicaltrials_resource:NCT00064402/arm-group/c4ca4238a0b923820dcc509a6f75849b]

NCT00064402 arm group c81e728d9d4c2f636f067f89cc14862c [clinicaltrials_resource:NCT00064402/arm-group/c81e728d9d4c2f636f067f89cc14862c]

NCT00064402 arm group e4da3b7fbbce2345d7772b0674a318d5 [clinicaltrials_resource:NCT00064402/arm-group/e4da3b7fbbce2345d7772b0674a318d5]

NCT00064402 arm group eccbc87e4b5ce2fe28308fd9f2a7baf3 [clinicaltrials_resource:NCT00064402/arm-group/eccbc87e4b5ce2fe28308fd9f2a7baf3]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of this stu ...... t in patients with COPD

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Determine the Safety and Effic ...... reatment of Subjects With COPD

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

percent change in trough FEV1 from study baseline to the end of the dosing interval (12 hours post-second dose for the BID treatment arms and 24 hours postdose for the QD treatment arm) over the double-blind period. Weeks -2, 0, 3, 6, 9, 12 [clinicaltrials_resource:59eb8898935fa116028482425eb9a85d]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

percent change in trough FEV1 from study baseline to the end of the dosing interval (12 hours post-second dose for the BID treatment arms and 24 hours postdose for the QD treatment arm) over the double-blind period. Weeks -2, 0, 3, 6, 9, 12 [clinicaltrials_resource:0a560b713bae6d2cb621432808e94baa]

percent change in trough FEV1 from study baseline to the end of the dosing interval (12 hours post-second dose for the BID treatment arms and 24 hours postdose for the QD treatment arm) over the double-blind period. Weeks -2, 0, 3, 6, 9, 12 [clinicaltrials_resource:2ee7babb7ce3a63983634ef8b53aa2cb]

percent change in trough FEV1 from study baseline to the end of the dosing interval (12 hours post-second dose for the BID treatment arms and 24 hours postdose for the QD treatment arm) over the double-blind period. Weeks -2, 0, 3, 6, 9, 12 [clinicaltrials_resource:3774b64620d8ebcf6600cda91ca82f87]

percent change in trough FEV1 from study baseline to the end of the dosing interval (12 hours post-second dose for the BID treatment arms and 24 hours postdose for the QD treatment arm) over the double-blind period. Weeks -2, 0, 3, 6, 9, 12 [clinicaltrials_resource:3863d916e69b6aa13c8a688d17b8ac85]

percent change in trough FEV1 from study baseline to the end of the dosing interval (12 hours post-second dose for the BID treatment arms and 24 hours postdose for the QD treatment arm) over the double-blind period. Weeks -2, 0, 3, 6, 9, 12 [clinicaltrials_resource:4c181dfda88f2809bca15c6e704b19d0]

percent change in trough FEV1 from study baseline to the end of the dosing interval (12 hours post-second dose for the BID treatment arms and 24 hours postdose for the QD treatment arm) over the double-blind period. Weeks -2, 0, 3, 6, 9, 12 [clinicaltrials_resource:4eefff59c65caaacda9c01641449137f]

percent change in trough FEV1 from study baseline to the end of the dosing interval (12 hours post-second dose for the BID treatment arms and 24 hours postdose for the QD treatment arm) over the double-blind period. Weeks -2, 0, 3, 6, 9, 12 [clinicaltrials_resource:54ae819f69b7033df3a5e2c22f875538]

percent change in trough FEV1 from study baseline to the end of the dosing interval (12 hours post-second dose for the BID treatment arms and 24 hours postdose for the QD treatment arm) over the double-blind period. Weeks -2, 0, 3, 6, 9, 12 [clinicaltrials_resource:54fd3f9a85ca8dc92502c7622dc4dc52]

percent change in trough FEV1 from study baseline to the end of the dosing interval (12 hours post-second dose for the BID treatment arms and 24 hours postdose for the QD treatment arm) over the double-blind period. Weeks -2, 0, 3, 6, 9, 12 [clinicaltrials_resource:5ec731e48aebc2e4c1495a133728ac47]

percent change in trough FEV1 from study baseline to the end of the dosing interval (12 hours post-second dose for the BID treatment arms and 24 hours postdose for the QD treatment arm) over the double-blind period. Weeks -2, 0, 3, 6, 9, 12 [clinicaltrials_resource:845fb063efc9a0aba6e8f4983f4df94e]

completion date [clinicaltrials_vocabulary:completion-date]

2004-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

This was a double-blind ...... Sunovion Pharmaceuticals Inc.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00064402 [clinicaltrials_resource:fdb4e979a73d1806bc0eb83466858d82]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2003-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

arformoterol tartrate inhalation solution [clinicaltrials_resource:1b0d79ae671d8659f97a900952da457c]

arformoterol tartrate inhalation solution [clinicaltrials_resource:1d790a7308d38a76ce73a77c47e6a9c5]

Salmeterol [clinicaltrials_resource:4fb8f4ef786181b98518f5f4f53aa479]

arformoterol tartrate inhalation solution [clinicaltrials_resource:637c9087587952f74130cac7e1eed7d8]

Placebo [clinicaltrials_resource:b1793f91a2897f38e33c4c5f50ea8dc5]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Pharmaceutical Solutions [clinicaltrials_resource:0cdadce3aff0a843c931b99f2680426f]

Salmeterol [clinicaltrials_resource:280eecd21fa4bb7af831dbefbfca1721]

Formoterol [clinicaltrials_resource:7c9974a4b99030777b15c6c12159d4ac]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2012-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Sunovion [clinicaltrials_resource:eb18fe99130b8e9bb1f6902cafe0f49f]

location [clinicaltrials_vocabulary:location]

Pulmonary & Sleep Associates of Jasper, PC [clinicaltrials_resource:356949d8dcfc9e63eae69e3390cf78a7]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00064402

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

5

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Double-Blind, Double-Dummy, ...... Obstructive Pulmonary Disease

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

091-051

http://www.w3.org/2001/XMLSchema#string

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:be4cea82cb21bbda79c939a4d720315b]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2004-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

Sunovion [clinicaltrials_resource:eb18fe99130b8e9bb1f6902cafe0f49f]

start date [clinicaltrials_vocabulary:start-date]

2002-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00064402 study design [clinicaltrials_resource:96ed2ccee68f2ac22e33451ec133784f]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00064402

verification date [clinicaltrials_vocabulary:verification-date]

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00064402

http://www.w3.org/2001/XMLSchema#string

title

Determine the Safety and Effic ...... reatment of Subjects With COPD

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Determine the Safety and Effic ...... D [clinicaltrials:NCT00064402]

@en